Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 141 participants.

Also called NCT05145283

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 141 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05145283
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05145283. Randomized; double masking; primary purpose prevention. Start 2022-03-16 (actual); primary completion 2026-01-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation
Acronym
PAIR-TAVI
Condition
Acute Ischemic Stroke
Condition
Acute Renal Injury
Intervention (Drug)
Conestat alfa (Ruconest®)
Intervention (Drug)
NaCl 0.9%)
Lead sponsor
University Hospital, Basel, Switzerland (class: other)
Collaborator
Swiss National Science Foundation (class: other)
Collaborator
Pharming Technologies B.V. (class: industry)

Record details

Record id
cardio:ct-nct05145283
Content hash
232155fd2da040e326dcb258218c38640159d709229a682479e7fe6e048e2eaf